^
Association details:
Biomarker:RET fusion
Cancer:Breast Cancer
Drug:Retevmo (selpercatinib) (RET inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Non Small Cell Lung Cancer)
New
Title:

The China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers

Excerpt:
Innovent Biologics, Inc...is pleased to see that the National Medical Products Administration (NMPA) of China has approved the New Drug Application (NDA) for selpercatinib (40mg & 80mg capsules) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion...
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

CT011 - Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers

Published date:
03/10/2021
Excerpt:
...Thirty-two pts with RET fusion-positive non-lung/non-thyroid cancers included 12 unique tumor types: 9 pancreatic, 9 colon, 2 each of breast, salivary, sarcoma, and unknown primary, and 1 each of carcinoid, rectal neuroendocrine, small intestine, xanthogranuloma, ovarian, and pulmonary carcinosarcoma. Objective responses were observed in 9 unique cancer types including colon, pancreatic, carcinoid, small intestine, salivary, xanthogranuloma, breast, ovarian, and sarcoma, and 5 additional patients had stable disease lasting ≥ 16 weeks. Median time to response was 1.9 months (range 0.7-7.3). Selpercatinib demonstrated promising antitumor activity in RET fusion-positive non-lung/non-thyroid cancers, including multiple treatment-refractory GI malignancies.
Trial ID:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Abstract 5236: Complete response to selpercatinib (LOXO-292), a highly selective RET inhibitor, in a patient with RET fusion-positive breast cancer

Published date:
05/15/2020
Excerpt:
Selpercatinib demonstrated anti-tumor activity in a patient with RET fusion-positive breast cancer.
DOI:
10.1158/1538-7445.AM2020-5236